http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2506015-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5f07d2ff10aba4f23580e38140283861 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5743 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
filingDate | 2011-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2012-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-2506015-A1 |
titleOfInvention | A prognostic and therapeutic signature for malignant melanoma |
abstract | The present invention relates to a method of predicting the course of disease in a patient having a malignant melanoma, the method comprising determining in melanoma cells comprised in a sample obtained from said malignant melanoma the presence or amount of at least five biomarkers selected from the group comprising or consisting of MTAP, PTEN, Bax, Bcl-X, β-Catenin, CD20, Cox-2, CD49d and MLH1, wherein the absence or decreased amount of MTAP and β-Catenin and/or the presence or increased amount of PTEN, Bax, Bcl-X, CD20, Cox-2, CD49d and MLH1, is associated with a disadvantageous course of disease. The present invention further relates to a method of preparing a tailored pharmaceutical composition for a patient having a malignant melanoma, a kit for predicting the course of disease in a patient having a malignant melanoma, a kit for preparing a tailored pharmaceutical composition for a patient having a malignant melanoma as well as a pharmaceutical composition for use in treating or preventing malignant melanoma. |
priorityDate | 2011-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1079.